Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Panel OKs Taiho’s GIST Med, ViiV/Janssen’s HIV Combo and More for Approval
May 31, 2022
- 7 New Probable Cases of Pediatric Hepatitis Reported in Japan
May 31, 2022
- Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
- Lawmakers’ League on Vaccines Urges Enhanced R&D System for Homegrown Jabs
May 30, 2022
- Orphan Tag Granted for Eisai’s ALS Drug, 3 Other APIs
May 30, 2022
- Deregulation Panel Urges Better Data Infrastructure, DCT Promotion to Boost Drug Discovery in Japan
May 30, 2022
- Japan Approves Additional Indications, Dosages for Rinvoq, Adcetris, Rozex, and More
May 27, 2022
- Japan Begins Second COVID Booster for Age 60-Plus, High-Risk Adults
May 26, 2022
- MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
- Japan Panel OKs Risk Management Measures for Potential Revlimid Generics
May 25, 2022
- MHLW to Issue Guidances on eConsent, Drug Delivery for Virtual Clinical Trials: Official
May 25, 2022
- Japan Regulators Warn of Monkeypox Cases
May 25, 2022
- MHLW Clarifies LVEF-Related Labeling Rule for Heart Failure Drugs: Q&A
May 24, 2022
- G7 Health Ministers Unite for Boosting Measures for Future Pandemics, AMR
May 24, 2022
- 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
- Japanese Regulators to Accept Online NDA Submissions from July
May 23, 2022
- Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
- 12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
May 23, 2022
- PMDA Reviewing New Safety Risks for Opdivo, Keytruda and More
May 23, 2022
- MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…